Please use this identifier to cite or link to this item: doi:10.22028/D291-37942
Title: Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma : A Series of 12 Patients
Author(s): DeTemple, Viola K.
Hassel, Jessica C.
Sachse, Michael M.
Grimmelmann, Imke
Leiter, Ulrike
Gebhardt, Christoffer
Eckardt, Julia
Pföhler, Claudia
Angela, Yenny
Hübbe, Hanna
Gutzmer, Ralf
Language: English
Title: Cancers
Volume: 14
Issue: 21
Publisher/Platform: MDPI
Year of Publication: 2022
Free key words: advanced basal cell carcinoma
hedgehog inhibitor reinduction
sequential treatment
checkpoint inhibition
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure. Retrospective data analysis was performed with 12 patients with aBCC (locally advanced (n = 8)/metastatic (n = 4)). These patients (male:female 6:6, median age 68 years) initially received HHIs, leading to complete/partial response (66%) or stable disease (33%). Median treatment duration was 20.8 (2–64.5) months until discontinuation due to progression (n = 8), adverse events (n = 3), or patient request (n = 1). Subsequent PD1 inhibition (pembrolizumab 42%, cemiplimab 58%) yielded a partial response (8%), stable disease (33%), or progression (59%). Median treatment duration was 4.1 (0.8–16.3) months until discontinuation due to progression (n = 9), adverse events (n = 1), patient request (n = 1), or missing drug approval (n = 1). HHI reinduction resulted in complete/partial response (33%), stable disease (50%), or progression (17%). Median treatment duration was 3.6 (1–29) months. Response duration in the four responding patients was 2–29+ months. Thus, a subgroup of patients with aBCC responded to reinduction of HHI following PD1i failure. Therefore, this sequential treatment represents a feasible treatment option.
DOI of the first publication: 10.3390/cancers14215469
Link to this record: urn:nbn:de:bsz:291--ds-379428
ISSN: 2072-6694
Date of registration: 11-Nov-2022
Faculty: M - Medizinische Fakultät
Department: M - Dermatologie
Professorship: M - Keiner Professur zugeordnet
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
cancers-14-05469-v2.pdf1,06 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons